BNO 0.00% 1.0¢ bionomics limited

Ann: BNC105 Achieves High Response Rate in Ovaria, page-3

  1. 57 Posts.
    lightbulb Created with Sketch. 2
    re: Ann: BNC105 Achieves High Response Rate i... This is a non-event in spite of the PR headlines. 15 patients do not prove anything. It seems to have better outcome than mesathelioma trial.

    The trial of renal cell carcinoma is the main event for Bionomics. I thought that those results would be out by now. Well.. they WILL be out by end of March. Keeping fingers crossed!
 
watchlist Created with Sketch. Add BNO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.